CA2774458C - Astn1 and/or znf671 methylation for detection of cervical carcinoma - Google Patents
Astn1 and/or znf671 methylation for detection of cervical carcinoma Download PDFInfo
- Publication number
- CA2774458C CA2774458C CA2774458A CA2774458A CA2774458C CA 2774458 C CA2774458 C CA 2774458C CA 2774458 A CA2774458 A CA 2774458A CA 2774458 A CA2774458 A CA 2774458A CA 2774458 C CA2774458 C CA 2774458C
- Authority
- CA
- Canada
- Prior art keywords
- methylation
- znf671
- astn1
- dna
- hpv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000011987 methylation Effects 0.000 title claims abstract description 76
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 76
- 208000019065 cervical carcinoma Diseases 0.000 title claims abstract description 26
- 238000001514 detection method Methods 0.000 title claims description 35
- 238000000034 method Methods 0.000 claims abstract description 61
- 102100028943 Zinc finger protein 671 Human genes 0.000 claims abstract description 35
- 101000915607 Homo sapiens Zinc finger protein 671 Proteins 0.000 claims abstract description 33
- 102100027708 Astrotactin-1 Human genes 0.000 claims abstract description 25
- 238000007855 methylation-specific PCR Methods 0.000 claims abstract description 17
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 10
- 101710120624 Astrotactin-1 Proteins 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 31
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 24
- 102000040945 Transcription factor Human genes 0.000 claims description 10
- 108091023040 Transcription factor Proteins 0.000 claims description 10
- 238000009595 pap smear Methods 0.000 claims description 10
- 101710185494 Zinc finger protein Proteins 0.000 claims description 5
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims description 5
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 2
- 101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 abstract description 28
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 101710180773 Zinc finger protein 671 Proteins 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 49
- 239000013615 primer Substances 0.000 description 35
- 206010028980 Neoplasm Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 18
- 102100022105 Relaxin-3 receptor 1 Human genes 0.000 description 14
- 101710117864 Relaxin-3 receptor 1 Proteins 0.000 description 14
- 201000009030 Carcinoma Diseases 0.000 description 12
- 102100032449 EGF-like repeat and discoidin I-like domain-containing protein 3 Human genes 0.000 description 12
- 101001016381 Homo sapiens EGF-like repeat and discoidin I-like domain-containing protein 3 Proteins 0.000 description 12
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 12
- 239000007850 fluorescent dye Substances 0.000 description 11
- 239000002987 primer (paints) Substances 0.000 description 10
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 8
- 102100032818 Integrin alpha-4 Human genes 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108091029523 CpG island Proteins 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010008263 Cervical dysplasia Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010049959 Discoidins Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102100034944 Relaxin-3 Human genes 0.000 description 1
- 101710113452 Relaxin-3 Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004745 cervical carcinogenesis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09011941.3 | 2009-09-18 | ||
| EP09011941A EP2308998A1 (de) | 2009-09-18 | 2009-09-18 | Verfahren zur frühen Diagnose von Karzinomen des Anogenitaltraktes |
| PCT/EP2010/005735 WO2011032721A1 (de) | 2009-09-18 | 2010-09-17 | Verfahren zur frühen diagnose von karzinomen des anogenitaltraktes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2774458A1 CA2774458A1 (en) | 2011-03-24 |
| CA2774458C true CA2774458C (en) | 2021-04-27 |
Family
ID=41564137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2774458A Active CA2774458C (en) | 2009-09-18 | 2010-09-17 | Astn1 and/or znf671 methylation for detection of cervical carcinoma |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8575326B2 (enExample) |
| EP (2) | EP2308998A1 (enExample) |
| JP (1) | JP5491631B2 (enExample) |
| CA (1) | CA2774458C (enExample) |
| DK (1) | DK2478117T3 (enExample) |
| ES (1) | ES2431301T3 (enExample) |
| WO (1) | WO2011032721A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102082098B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CN104513851B (zh) * | 2013-10-08 | 2017-01-11 | 陈永恩 | 侦测膀胱癌的新颖表基因生物标记及其方法 |
| DE102015101555A1 (de) * | 2015-02-03 | 2016-08-04 | Oncgnostics GmbH BioInstrumentezentrum Jena | Verfahren und Kit zur Bestimmung des Risikos einer Entwicklung eines Zervixkarzinoms oder einer seiner malignen Vorstufen |
| US12331360B2 (en) * | 2017-09-29 | 2025-06-17 | Oncgnostics Gmbh | Risk determination for neoplasia and cancer |
| CN107760788B (zh) * | 2017-12-05 | 2021-03-02 | 武汉艾米森生命科技有限公司 | 一种检测宫颈细胞基因甲基化的核酸组合及试剂盒与应用 |
| US20220106644A1 (en) * | 2019-01-24 | 2022-04-07 | Mayo Foundation For Medical Education And Research | Detecting endometrial cancer |
| CN110452984A (zh) * | 2019-07-29 | 2019-11-15 | 韩林志 | 一种用于宫颈癌甲基化检测的甲基化基因组合、引物和探针组合、试剂盒及其使用方法 |
| CA3154354A1 (en) | 2019-10-31 | 2021-05-06 | William R. Taylor | Detecting ovarian cancer |
| WO2021133999A1 (en) * | 2019-12-23 | 2021-07-01 | Active Motif, Inc. | Methods and kits for the enrichment and detection of dna and rna modifications and functional motifs |
| CA3208505A1 (en) | 2021-02-26 | 2022-09-01 | Oncgnostics Gmbh | Diagnosis and risk determination for head and neck cancer |
| CN112941189B (zh) * | 2021-05-06 | 2023-07-21 | 中南大学 | 宫颈癌早筛分子标志物znf671基因甲基化检测的引物探针组合物及试剂盒和使用方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| US20070105105A1 (en) * | 2003-05-23 | 2007-05-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| AU2004256425A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2009
- 2009-09-18 EP EP09011941A patent/EP2308998A1/de not_active Withdrawn
-
2010
- 2010-09-17 ES ES10765749T patent/ES2431301T3/es active Active
- 2010-09-17 DK DK10765749.6T patent/DK2478117T3/da active
- 2010-09-17 US US13/496,812 patent/US8575326B2/en active Active
- 2010-09-17 EP EP10765749.6A patent/EP2478117B1/de active Active
- 2010-09-17 JP JP2012529163A patent/JP5491631B2/ja active Active
- 2010-09-17 CA CA2774458A patent/CA2774458C/en active Active
- 2010-09-17 WO PCT/EP2010/005735 patent/WO2011032721A1/de not_active Ceased
-
2013
- 2013-08-29 US US14/013,272 patent/US9228238B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2431301T3 (es) | 2013-11-25 |
| EP2478117A1 (de) | 2012-07-25 |
| JP2013505007A (ja) | 2013-02-14 |
| CA2774458A1 (en) | 2011-03-24 |
| US8575326B2 (en) | 2013-11-05 |
| EP2478117B1 (de) | 2013-07-31 |
| US20120208180A1 (en) | 2012-08-16 |
| JP5491631B2 (ja) | 2014-05-14 |
| WO2011032721A1 (de) | 2011-03-24 |
| EP2308998A1 (de) | 2011-04-13 |
| US9228238B2 (en) | 2016-01-05 |
| US20130344479A1 (en) | 2013-12-26 |
| DK2478117T3 (da) | 2013-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2774458C (en) | Astn1 and/or znf671 methylation for detection of cervical carcinoma | |
| CN110578001B (zh) | 用于检测宫颈癌相关基因甲基化的检测试剂盒及其使用方法 | |
| US7820386B2 (en) | Cancer screening method | |
| EP2626435B1 (en) | Detection and prognosis of cervical cancer | |
| CA2883671A1 (en) | Method for screening cancer | |
| CN113249485A (zh) | 一种用于宫颈癌相关基因甲基化检测的引物探针组合和试剂盒及其应用 | |
| CN110564857A (zh) | 一种用于早期宫颈癌检测的组合物及试剂盒 | |
| CN110753761A (zh) | 检测hpv诱导的浸润性癌症、非hpv诱导的妇科癌症和肛门生殖器癌症以及它们的高级前体病变的甲基化分类器 | |
| CN117904303B (zh) | Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用 | |
| CN116875700A (zh) | 一种子宫内膜良恶性病变的生物标志物及其应用 | |
| CN107475443A (zh) | 子宫颈癌检测套组 | |
| CN117265096A (zh) | 用于宫颈高级别病变和宫颈癌早期检测的试剂盒 | |
| US20100285443A1 (en) | Diagnostic Methods for Diseases Caused by a HPV Infection Comprising Determining the Methylation Status of the HPV Genome | |
| TWI716883B (zh) | 腫瘤標誌物、甲基化檢測試劑、試劑盒及其應用 | |
| CN116144782A (zh) | 一种用于肺癌检测的组合标志物及其应用 | |
| CN115976202A (zh) | 一种用于检测宫颈癌相关基因甲基化的引物探针组合和试剂盒 | |
| CN116024342B (zh) | 用于检测宫颈癌或癌前病变的核酸产品、试剂盒及应用 | |
| KR20220052461A (ko) | 난소암 진단 또는 감별진단을 위한 마이크로rna-1246 및 이의 용도 | |
| CN114507730B (zh) | 检测基因甲基化的试剂在宫颈癌诊断中的应用以及试剂盒 | |
| CN118685528B (zh) | 一种宫颈癌基因甲基化检测的生物标记物、引物探针组合及其应用 | |
| CN120330333A (zh) | 用于体外检测子宫内膜癌的甲基化标志物ocel1基因、olig2基因及其用途 | |
| CN116064814A (zh) | 用于检测鼻咽癌特异性标志物甲基化的试剂盒及应用 | |
| CN120464734A (zh) | 用于检测卵巢癌的组合物及其用途 | |
| CN121087169A (zh) | 一种用于检测宫颈癌及宫颈高级别病变的组合物、试剂盒及用途 | |
| CN118792405A (zh) | 一种诊断宫颈癌的甲基化标志物组合及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150916 |